Two different “takes” from the results of the CHAARTED trial

In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …

Disulfiram in prostate cancer revisited (this time with copper supplementation)

Not so long ago (back in late 2013), Schweizer et al. reported data from a very small trial of an old drug called disulfiram (also known as Antabuse) in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …

Do [11C]choline PET/CT scan data change clinical decision-making?

The practical value of any type of diagnostic and prognostic technology can only really be assessed in the context of whether the data generated by that technology change the way that physicians treat (or make recommendations about treatment for) individual patients. … READ MORE …

Neurocrine (small cell) cancer of the prostate: an update

A new review article in the open access journal Oncology offers some key information about neuroendocrine (small-cell) carcinomas of the prostate (and why they offer essential lessons about the diagnosis and management of prostate cancer). … READ MORE …

NICE rejects Provenge as a treatment for mCRPC based on cost

The National Institute for Health and Clinical Excellence (NICE) in the UK has issued a statement that, according to preliminary draft guidelines, it has rejected the use of sipuleucel-T (Provenge) to treat patients with metastatic prostate cancer before they have received chemotherapy. … READ MORE …

Evolution of the mCRPC treatment landscape

A new article by Jeffress in the cancer business publication OBR Green discusses the changing patterns of use of  the various approved drugs in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Current options for treatment of radiorecurrent, localized prostate cancer

For men who choose to have radiotherapy (external photon beam, external proton beam, or brachytherapy of some type) as first-line therapy for localized prostate cancer, a major issue is, “What if the cancer recurs after treatment?” … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,154 other followers